Stroke
Conditions
Interventions
Trail group:nao xin qing +Ginkgo biloba simulation agent
Positive control group:Ginkgo biloba + nao xin qing simulation agent
Placebo group:nao xin qing simulation agent +Ginkgo biloba simulation agent
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Applicants who are diagnosed as the patients with cerebral atherosclerotic infarction according to the diagnosis standard; 2. Applicants who suffer from stroke, blood stasis according to the TCM diagnosis standard; 3. Patients who are attacked 2 weeks before and in past 3 months; 4. NIHSS score from 5 to 25; 5. Patients who are at the age of over 40 and under 80(including 40 and 80); 6. Patients with first onset or patients with recurrent stroke before the onset of the disease has been fully recovered, the MRS is divided into 0-1 points; 7. Applicants who voluntarily make cooperation to complete the research plan.
Exclusion criteria
Exclusion criteria: 1. Applicants who are attacked by cerebral hemorrhage in past half year; 2. Applicants who suffer from cerebral embolism caused by brain tumor, brain trauma, brain parasite disease, dysbolism, rheumatic heart disease, coronary heart disease or other heart diseases with atrial fibrillation; 3. Applicants who suffer from diseases for example osteoarthritis, rheumatoid arthritis, gouty arthritis induced physical activities dysfunction may affect the function of nerves; 4. Applicants who suffer from diseases for example serious heart and lung system disease, and chronic liver and renal function disorder, including hepatic function damage ALT, AST, > 2 times of normal; the renal function damage (BUN > 1.2 times of normal; Cr > normal); 5. Pregnant woman or suckling period woman; 6. Disabled people according to the law (blind, deaf, dumb, dysgnosia, alloeosis, extremity disability); 7. Applicants who are known to have an allergy to this drug, or with allergic constitution; 8. Applicants who are included in other clinical trials in past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIHSS;SSQOL; | — |
Secondary
| Measure | Time frame |
|---|---|
| MRS;Barthel Scale;TCM syndrome scores;Single syndrome scores; | — |
Countries
China
Contacts
Public ContactLiu Ming
West China Hospital, Sichuan University
Outcome results
None listed